Risk-Adjusted Buy Rating on Wave Life Sciences: Differentiated Obesity Mechanism, Reset Valuation, and Long-Term Upside Despite 400 mg Uncertainty
at www.tipranks.com (Fri, 27-Mar 5:45 AM)
WVE-007 Delivers Clinically Meaningful Reductions in Visceral Fat and Waist Circumference After Just One Dose, Phase 1 Data Reveal
Market Chameleon (Thu, 26-Mar 7:49 AM)
Wave Life Sciences Regains Full Control of WVE-006, Targets Accelerated FDA Pathway for Alpha-1 Antitrypsin Deficiency Therapy
Market Chameleon (Mon, 2-Feb 9:09 AM)
Wave Life Sciences Preps Key J.P. Morgan Healthcare Conference Presentation Amid Diverse RNA Therapeutics Pipeline
Market Chameleon (Tue, 6-Jan 11:44 AM)
